SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as $8.84 and last traded at $8.45, with a volume of 655541 shares trading hands. The stock had previously closed at $8.65.
Analyst Ratings Changes
SOPH has been the subject of a number of recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research raised their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Finally, Zacks Research raised SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $10.00.
Get Our Latest Report on SOPHiA GENETICS
SOPHiA GENETICS Trading Down 2.3%
The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a market capitalization of $708.91 million, a price-to-earnings ratio of -7.35 and a beta of 0.96. The business has a 50 day simple moving average of $6.25 and a 200-day simple moving average of $5.35.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.
Insider Buying and Selling at SOPHiA GENETICS
In related news, CEO Jurgi Camblong sold 50,069 shares of the firm's stock in a transaction on Friday, June 26th. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20. Following the sale, the chief executive officer directly owned 3,601,493 shares in the company, valued at $20,888,659.40. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the sale, the insider directly owned 590,887 shares in the company, valued at $4,307,566.23. This represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 313,592 shares of company stock valued at $1,927,565. 4.88% of the stock is currently owned by corporate insiders.
Institutional Trading of SOPHiA GENETICS
Several hedge funds and other institutional investors have recently modified their holdings of SOPH. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $49,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS in the 3rd quarter valued at approximately $49,000. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS during the 1st quarter worth approximately $50,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. Institutional investors and hedge funds own 31.59% of the company's stock.
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider SOPHiA GENETICS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.
While SOPHiA GENETICS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
